Mechanistic insights into bacteriophage properties required for enhanced therapeutic potential at mucosal surfaces

增强粘膜表面治疗潜力所需的噬菌体特性的机制见解

基本信息

  • 批准号:
    10583463
  • 负责人:
  • 金额:
    $ 54.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-01 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

Project Summary The human mucosal surface is a complex ecosystem made of bacteria, viruses, epithelial cells, mucus, and molecules such as proteins, sugars, and other solutes whose balance is key to the health of the host. It is also the first line of defense against invading bacteria, and a site of colonization by diverse microbiota. Some members of this microbiota, termed pathobionts, cause serious local and systemic infections. However, the use of antibiotics to treat these infections is a classic Catch-22; there may temporary relief but down the road the very solution generates a bigger version of the original problem. Whereas one may rid the environment of the pathobiont, one also eliminates the beneficial microbiota that antagonize the pathobiont while creating a selection that further increases rates of resistance. In addition, the destruction of the balance of the ecosystem further predisposes that system to invasion by other pathobionts, and, in the long run, increases the risk of infection and inflammation. There is a real need to develop an alternative line of antibacterials that lack these limitations. The overall objective of this project is to discover bacteriophage, viruses that infect and kill bacteria, that are specifically active against drug-resistant pathobionts in the complex environment of a human mucosal surface. These phage should be specific for their bacterial target, as well as have evolved features that promote enhanced activity in the face of the complexity presented by such surfaces. Furthermore, should the pathobiont spread systemically, these phage should synergize with conventional antibiotics while simultaneously generating a steep evolutionary path for the emergence of new resistance. Using one of the world’s largest collections of therapeutic phages and characterizing them for enhanced activity in human mucosal biomimetics, the research program described here lays the foundation for the development of a novel class of mucosal-active antibacterials that clear problematic pathobionts while simultaneously maintaining balance of the native microbiota.
项目摘要 人体粘膜表面是一个由细菌、病毒、上皮细胞、 粘液,以及蛋白质、糖和其他溶质等分子,它们的平衡对 宿主的健康状况。它也是抵御入侵细菌的第一道防线,也是 由不同的微生物群进行的定居。这个微生物群中的一些成员,被称为病原体, 造成严重的局部和系统感染。然而,使用抗生素来治疗这些 感染是一种典型的第二十二条军规;可能会暂时缓解,但最终会解决问题 生成原始问题的更大版本。然而,人们可能会摆脱环境中的 病原体,同时也消除了对抗病毒菌的有益微生物群 创造一种选择,进一步增加抵抗率。此外,对世界遗产的破坏 生态系统的平衡进一步使该系统容易受到其他病原体的入侵,并且, 从长远来看,会增加感染和发炎的风险。确实有必要发展 另一种没有这些局限性的抗菌药。 这个项目的总体目标是发现噬菌体,即感染和杀死的病毒。 细菌,这种细菌对复合体中的耐药病原体具有特定的活性 人体粘膜表面的环境。这些噬菌体应该是针对它们的细菌的 目标,以及已进化的功能,以促进在面对 由这样的表面呈现的复杂性。此外,如果病原体蔓延 从系统上讲,这些噬菌体应该与常规抗生素协同作用,同时 为新的抗药性的出现创造了一条陡峭的进化道路。使用其中一种 世界上最大的治疗噬菌体集合及其增强活性的特征 在人类粘膜仿生学方面,这里描述的研究计划为 一类新型黏膜活性抗菌药的研制 同时维持本地微生物区系的平衡。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANTHONY W MARESSO其他文献

ANTHONY W MARESSO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANTHONY W MARESSO', 18)}}的其他基金

Sugar regulation of EHEC virulance
EHEC毒力的糖调节
  • 批准号:
    10661099
  • 财政年份:
    2022
  • 资助金额:
    $ 54.26万
  • 项目类别:
Sugar regulation of EHEC virulance
EHEC毒力的糖调节
  • 批准号:
    10599476
  • 财政年份:
    2022
  • 资助金额:
    $ 54.26万
  • 项目类别:
Mechanistic insights into bacteriophage properties required for enhanced therapeutic potential at mucosal surfaces
增强粘膜表面治疗潜力所需的噬菌体特性的机制见解
  • 批准号:
    10357968
  • 财政年份:
    2021
  • 资助金额:
    $ 54.26万
  • 项目类别:
Sugar regulation of EHEC virulence
肠出血性大肠杆菌毒力的糖调节
  • 批准号:
    10203813
  • 财政年份:
    2020
  • 资助金额:
    $ 54.26万
  • 项目类别:
Sugar regulation of EHEC virulence
肠出血性大肠杆菌毒力的糖调节
  • 批准号:
    10065360
  • 财政年份:
    2020
  • 资助金额:
    $ 54.26万
  • 项目类别:
The Genomics and Antagonism of Pathobiont Colonization
致病生物定植的基因组学和拮抗作用
  • 批准号:
    10160780
  • 财政年份:
    2019
  • 资助金额:
    $ 54.26万
  • 项目类别:
The Genomics and Antagonism of Pathobiont Colonization
致病生物定植的基因组学和拮抗作用
  • 批准号:
    10601129
  • 财政年份:
    2019
  • 资助金额:
    $ 54.26万
  • 项目类别:
Branched Chain Amino Acid Metabolism During Anthrax
炭疽病期间的支链氨基酸代谢
  • 批准号:
    9807632
  • 财政年份:
    2019
  • 资助金额:
    $ 54.26万
  • 项目类别:
The Genomics and Antagonism of Pathobiont Colonization
致病生物定植的基因组学和拮抗作用
  • 批准号:
    10396592
  • 财政年份:
    2019
  • 资助金额:
    $ 54.26万
  • 项目类别:
The Importance and Function of Heme Degrading Enzymes during Anthrax Disease
炭疽病期间血红素降解酶的重要性和功能
  • 批准号:
    9323699
  • 财政年份:
    2017
  • 资助金额:
    $ 54.26万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 54.26万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 54.26万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.26万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.26万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 54.26万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.26万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 54.26万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 54.26万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 54.26万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.26万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了